[
  {
    "ts": null,
    "headline": "Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion",
    "summary": "The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio",
    "url": "https://finnhub.io/api/news?id=4abb4342d34e90878773888d087d8163cf3476b6d92b992111363030136bba99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763479200,
      "headline": "Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion",
      "id": 137538330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio",
      "url": "https://finnhub.io/api/news?id=4abb4342d34e90878773888d087d8163cf3476b6d92b992111363030136bba99"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says Amgen (AMGN)’s New Drug Has Good Data",
    "summary": "We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer discussed. Cramer has recently started to discuss pharmaceutical giant Amgen Inc. (NASDAQ:AMGN) more frequently. Most of his discussions surround the firm’s Repatha drug that aims to reduce cholesterol and prevent […]",
    "url": "https://finnhub.io/api/news?id=23a220d483460790647e7586cbb1a65b39a192cfd013e9421fb9f77a804a2c76",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763473545,
      "headline": "Jim Cramer Says Amgen (AMGN)’s New Drug Has Good Data",
      "id": 137538331,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer discussed. Cramer has recently started to discuss pharmaceutical giant Amgen Inc. (NASDAQ:AMGN) more frequently. Most of his discussions surround the firm’s Repatha drug that aims to reduce cholesterol and prevent […]",
      "url": "https://finnhub.io/api/news?id=23a220d483460790647e7586cbb1a65b39a192cfd013e9421fb9f77a804a2c76"
    }
  },
  {
    "ts": null,
    "headline": "How to use the tax-loss selling occurring now to pick up quality stocks on the cheap",
    "summary": "Kevin Simpson on how to use this annual phenomenon to your advantage.",
    "url": "https://finnhub.io/api/news?id=e8449d281e805266fdfb6e00a367cb755b8a8d8d4d4688cbe8df21dd35958175",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763462160,
      "headline": "How to use the tax-loss selling occurring now to pick up quality stocks on the cheap",
      "id": 137539478,
      "image": "https://image.cnbcfm.com/api/v1/image/108226832-1763392836480-gettyimages-2247138010-mms16768_m2ynxbly.jpeg?v=1763392911&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Kevin Simpson on how to use this annual phenomenon to your advantage.",
      "url": "https://finnhub.io/api/news?id=e8449d281e805266fdfb6e00a367cb755b8a8d8d4d4688cbe8df21dd35958175"
    }
  },
  {
    "ts": null,
    "headline": "The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company",
    "summary": "Eli Lilly  might soon join them for a far different reason: the weight-loss bonanza.  This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker  Novo Nordisk  That is why investors shouldn’t assume the rally stops at a trillion.  Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.",
    "url": "https://finnhub.io/api/news?id=2f619276006f59ef7f4326c21becb1df015e7eb3446155dcf003afb73f07c53a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763461800,
      "headline": "The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company",
      "id": 137538225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Eli Lilly  might soon join them for a far different reason: the weight-loss bonanza.  This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker  Novo Nordisk  That is why investors shouldn’t assume the rally stops at a trillion.  Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.",
      "url": "https://finnhub.io/api/news?id=2f619276006f59ef7f4326c21becb1df015e7eb3446155dcf003afb73f07c53a"
    }
  },
  {
    "ts": null,
    "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid",
    "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
    "url": "https://finnhub.io/api/news?id=b3c10b9599bfc415a29f8084049be93a26016839e5d0e7a1b93d0f6a39b1a877",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763440990,
      "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid",
      "id": 137538333,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
      "url": "https://finnhub.io/api/news?id=b3c10b9599bfc415a29f8084049be93a26016839e5d0e7a1b93d0f6a39b1a877"
    }
  }
]